[Cetuximah given in combination for patients with colorectal cancer]
Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)
Record ID 32013000047
Danish
Authors' recommendations:
Colorectal cancer is the third most common cancer in Denmark after breast and lung cancer and the incidence is increasing. A HTA-report concludes that the effect of Cetuximah are:
- Cetuximab given in combination with irinocetan, even where another irinotecan containing regimen has failed
- The appropriate patient population is approximately 150 patients
- Has not been demonstrated significantly longer survival
- Side effecsts may occur in the form of acne-like rash and shortness of breath
- Treatment can lead to capacity challenges for the treating hospitals increased waiting times for cancer treatment generally
- The total annual cost is approximately 263,000 DKKR per patients
- With 150 patients, total annual costs will be almost 40 million Euro
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
http://www.sst.dk/publ/Publ2006/CEMTV/Laegemidler/Cetuximab.pdf
URL for additional information:
http://www.sst.dk/English/DACEHTA/Publications_alphabetical_order/Cetuximah%20given%20in%20combination%20for%20patients%20with%20colorectal%20cancer.aspx
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Denmark
MeSH Terms
- Antibodies, Monoclonal
Contact
Organisation Name:
Danish Centre for Evaluation and Health Technology Assessment
Contact Address:
National Board of Health, PO Box 1881, Islands Brygge 67, DK-2300 Copenhagen S, Denmark. Tel: 45 72 22 74 48; Fax: 45 72 22 74 07/67
Contact Name:
dacehta@sst.dk
Contact Email:
dacehta@sst.dk
Copyright:
Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.